First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.

Yakun Wang, Lin Shen, Rongbo Lin et al.|Journal of Clinical Oncology|2023

Cited by 32